This page is updated frequently with new Autoimmune-related patent applications.
440+ Autoimmune-related patent PDFs
|Detection of shed cd31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways|
The present invention stems from the finding that the extracellular domain of cd31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of cd31. A method for detecting shed cd31 is further disclosed.
Institut National De La Sante Et De La Recherche Medicale (inserm)
|Marker sequences for diagnosing and stratifying sle patients|
The present invention relates to methods for identifying markers for systemic lupus erythematosus (sle) and to the markers identified with the aid of this method, which can differentiate between sle and other autoimmune diseases on the one hand and between different sle subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in sle.
|Sequencing-directed selection of tumor theranostics|
The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins..
|Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay|
Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-mhc complexes are in many cases inadequate for a number of reasons.
The Johns Hopkins University
|Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto|
This disclosure relates to recombinant proteins comprising a gm-csf sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises n-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer..
Children's Healthcare Of Atlanta, Inc.
|Suprametallogels and uses thereof|
The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology
|Prenatal therapy to induce immune tolerance|
Constructs and methods for inducing immune tolerance during gestation, e.g. In utero, are provided.
Inserm (institut National De La Santé Et De La Recherche Médicale)
|Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier|
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.. .
|Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis|
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular
|Humanized anti-hla-dr antibodies|
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Withaferin a analogs and uses thereof
The present invention provides a novel class of withanolides that have been isolated from w. Somnifera under aeroponic conditions or produced semi-synthetically from withanolide natural products.
Arizona Board Of Regents On Behalf Of The University Of Arizona
Substituted amino triazoles useful as human chitinase inhibitors
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Oncoarendi Therapeutics Sp. Z O.o.
Indole carboxamide compounds
Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Amido compounds as roryt modulators and uses thereof
And wherein n1, n2, r1a, r1b, r2, r3, r4, r5, and r6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease..
Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are bruton's tyrosine kinase (btk) inhibitors.
Zhejiang Dtrm Biopharma Co. Ltd.
Salts and solid form of a btk inhibitor
Disclosed herein are processes for preparing 2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (i)), salts of compound (i) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (i) or a pharmaceutically acceptable salt thereof..
Principia Biopharma Inc.
Fumarate analogs and uses thereof
Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes..
Rigel Pharmaceuticals, Inc.
Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.
Human antibodies that bind cd22 and uses thereof
The present disclosure provides isolated monoclonal antibodies that specifically bind to cd22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.
Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
Described herein are novel compositions comprising il-27 or nfil-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..
The Brigham And Women's Hospital, Inc.
Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Incorporated
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons.. .
Type 1 Diabetes
Follow us on Twitter
This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.